Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer
26 avr. 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 26, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces First Quarter 2022 Results
12 avr. 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert’s Pivotal Clinical Trial
31 mars 2022 03h01 HE
|
Mainz BioMed NV
Multi-Center Study on Track to Commence in Late 2022Initiated Reimbursement Process with The Centers for Medicare and Medicaid Services BERKELEY, Calif. and MAINZ, Germany, March 31, 2022 (GLOBE...
Mainz Biomed to Ring Nasdaq Stock Market Closing Bell
21 mars 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 21, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study
17 mars 2022 03h01 HE
|
Mainz BioMed NV
Cutting Edge IVD Developer Sentinel Chosen to Provide Automated FIT Analysis SystemLeading Clinical Research Organization Alcedis Selected to Manage the Study - ColoFuture on track to complete...
Mainz Biomed Announces Year End 2021 Results
09 mars 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month
02 mars 2022 03h01 HE
|
Mainz BioMed NV
Mainz Biomed joins a collective of physicians, healthcare professionals, laboratories and healthcare organizations as part of the international Colorectal Cancer Awareness Month initiative ...
Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert
23 févr. 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach
14 févr. 2022 03h01 HE
|
Mainz BioMed NV
Laboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in EuropeLaboratory MVZ Dr. Stein + Kollegen...
Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board
09 févr. 2022 03h01 HE
|
Mainz BioMed NV
Former DANAHER, ROCHE & QIAGEN Business Development Executive with Over 25 Years of Experience within the Pharmaceuticals and Diagnostics Industry BERKELEY, Calif. and MAINZ, Germany, Feb. ...